Susan Johnson

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Richard E. Pratley, Michael A. Nauck, Anthony Barnett et al. · The Lancet Diabetes & Endocrinology · 2014 · 325 citations

Medicine, Pharmacology, Pharmacotherapy +17

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Åhrén, Susan Johnson, Murray Stewart et al. · Diabetes Care · 2014 · 226 citations

Medicine, Pharmacology, Pharmacotherapy +16

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross et al. · Diabetes Care · 2014 · 205 citations

Medicine, Endocrinology, Pharmacotherapy +17

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum et al. · American Journal of Clinical Dermatology · 2021 · 139 citations · Full text

Medicine, Dermatology, Pharmacology +14

Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia

Jennifer Christian, Bhakti Arondekar, Erin Buysman et al. · Journal of clinical lipidology · 2012 · 77 citations

Pharmacy, Nutrition, Pharmacoeconomics +14